- Home
- KALV
as 04-18-2025 1:38pm EST
KalVista Pharmaceuticals Inc is a pharmaceutical company, which focuses on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema and diabetic macular edema; and oral plasma kallikrein inhibitors. Geographically it operates throughout the region of the United States. The company is also conducting preclinical development on a novel, oral, Factor XIIa inhibitor program.
| Founded: | N/A | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 563.1M | IPO Year: | N/A |
| Target Price: | $24.83 | AVG Volume (30 days): | 729.1K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 8 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.72 | EPS Growth: | N/A |
| 52 Week Low/High: | $7.30 - $15.50 | Next Earning Date: | 03-12-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of KalVista Pharmaceuticals Inc. (KALV)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Palleiko Benjamin L | KALV | CHIEF EXECUTIVE OFFICER | Mar 6 '25 | Sell | $11.97 | 6,669 | $79,827.93 | 287,811 | |
| Audhya Paul K. | KALV | CHIEF MEDICAL OFFICER | Feb 22 '25 | Sell | $10.02 | 2,394 | $23,987.88 | 102,940 | |
| Yea Christopher | KALV | CHIEF DEVELOPMENT OFFICER | Feb 21 '25 | Sell | $10.02 | 1,918 | $19,218.36 | 93,952 | |
| Palleiko Benjamin L | KALV | CHIEF EXECUTIVE OFFICER | Feb 17 '25 | Sell | $9.82 | 5,104 | $50,142.72 | 287,811 | |
| Yea Christopher | KALV | CHIEF DEVELOPMENT OFFICER | Feb 17 '25 | Sell | $9.82 | 2,601 | $25,552.74 | 93,952 | |
| Audhya Paul K. | KALV | CHIEF MEDICAL OFFICER | Feb 17 '25 | Sell | $9.82 | 3,125 | $30,700.62 | 102,940 | |
| Venrock Healthcare Capital Partners III, L.P. | KALV | 10% Owner | Feb 12 '25 | Buy | $9.28 | 161,700 | $1,498,661.00 | 5,217,285 | |
| Venrock Healthcare Capital Partners III, L.P. | KALV | 10% Owner | Feb 7 '25 | Buy | $9.20 | 104,489 | $967,144.93 | 5,217,285 | |
| Venrock Healthcare Capital Partners III, L.P. | KALV | 10% Owner | Jan 30 '25 | Buy | $8.96 | 70,023 | $621,628.02 | 5,217,285 |
Latest KalVista Pharmaceuticals Inc. News
KALV Breaking Stock News: Dive into KALV Ticker-Specific Updates for Smart Investing
Pharmaceutical Technology
11 days ago
KalVista licenses commercialisation rights for HAE to Kaken in Japan
MT Newswires
11 days ago
KalVista Signs Deal With Kaken to Commercialize Hereditary Angioedema Treatment in Japan
Business Wire
11 days ago
KalVista Pharmaceuticals Enters Into Licensing Agreement With Kaken Pharmaceutical to Commercialize Sebetralstat for HAE in Japan
Business Wire
17 days ago
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire
19 days ago
KalVista Pharmaceuticals to Present at 24th Annual Needham Virtual Healthcare Conference
Clinical Trials Arena
24 days ago
KalVista Pharmaceuticals enrols all subjects in hereditary angioedema drug trial
MT Newswires
25 days ago
KalVista Pharmaceuticals Completes Participant Enrollment Ahead of Schedule for Pediatric Hereditary Angioedema Trial
Business Wire
25 days ago
KalVista Pharmaceuticals Announces Early Completion of Enrollment in KONFIDENT-KID Pediatric HAE Trial
Compare KALV vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "KALV KalVista Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.